Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12622000674730
Ethics application status
Approved
Date submitted
27/04/2022
Date registered
10/05/2022
Date last updated
26/09/2022
Date data sharing statement initially provided
10/05/2022
Type of registration
Prospectively registered
Titles & IDs
Public title
Extended Follow Up and Data Registry Substudy in Australia and New Zealand for the participants of ANZ 1501 POSNOC (POsitive Sentinel NOde Clearance) study.
Query!
Scientific title
ANZ 1501 POSNOC substudy: Extended Follow Up and Data Registry Substudy
Query!
Secondary ID [1]
307052
0
Nil
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
POSNOC
Query!
Linked study record
This is a substudy of Protocol RD-5103-001-13 (POSNOC), The POSNOC study is registered on both the ISRCTN and ClinicalTrials.gov as follows:
ISRCTN Registry ISRCTN54765244
ClinicalTrials.gov NCT02401685
Query!
Health condition
Health condition(s) or problem(s) studied:
Breast Cancer
326128
0
Query!
Condition category
Condition code
Cancer
316269
316269
0
0
Query!
Breast
Query!
Intervention/exposure
Study type
Observational
Query!
Patient registry
False
Query!
Target follow-up duration
Query!
Target follow-up type
Query!
Description of intervention(s) / exposure
Australian and New Zealand participants in the POSNOC study ((ISRCTN54765244, NCT02401685) will be invited to participate in this extended follow up and data registry substudy.
Data collection in this project will be obtained by:
1. One additional follow up in 2026 (when the final patient recruited to POSNOC has reached 5 years of follow up). Data will be collected from the participant's medical record to determine date of most recent contact, presence of recurrences or new breast cancer events, nature of any such events, vital status. Data linkage will be used where a patient cannot be contacted; and
2. Subsequent follow up by data linkage. The data will be requested from the respective national and jurisdictional data registries for Australia and New Zealand such as the Australian Institute of Health and Welfare (AIHW) and New Zealand’s Breast Cancer Foundation National Register (BCFNR). Data will be cleaned and securely stored on servers within the Breast Cancer Trials, Trials Department, Newcastle, NSW Australia.
Relevant data relating POSNOC will be forwarded to UK sponsors and incorporated into the POSNOC clinical trial dataset stored at Nottingham Clinical Trial Unit, Nottingham, UK. Identifying patient data signified with ‘*’ will not leave Australian territory.
+ Unique ID/POSNOC participant identifier
+ Surname (including any previous names)*
+ Given name/s*
+ Sex
+ Date of birth*
+ State (for Australian participants)*
+ Vital status at last follow up
+ Address*.
Applications using this information will be made to the Australian Institute of Health and Welfare (AIHW) and New Zealand’s Breast Cancer Foundation National Register (BCFNR) to link the following data to those participants:
+ Vital status/Current patient status
+ Date of death
+ Cause of death
+ ICD10AM code (AUS) for new cancers (i.e. International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, Australian Modification).
+ Date of new cancer diagnosis/Date of definitive diagnosis of NEW primary
+ Cancer details (type, site, size, topography and morphology)
This follow up and data collection via data linkage will collect further health status information to avoid causing unnecessary distress to the family, as it will avert inappropriate contact if the woman has died following discharge from hospital-based follow up. It will reduce losses to follow up and will also enable longer term follow up data (greater than 5 years) to be reported.
The objectives of the POSNOC Extended Follow Up and Data Registry substudy are the same as those of the main POSNOC study. The objective of this substudy is to increase the power of the study to address the questions.
It is expected that the addition of complete mortality and cancer incidence data from the Australian and New Zealand participants in addition to that collected in the UK will increase the power of the POSNOC study to determine whether adjuvant therapy alone is no worse than adjuvant therapy plus axillary treatment.
Main study: Protocol RD-5103-001-13 - A randomized controlled trial of axillary treatment in women with early stage breast cancer who have metastases in one or two sentinel nodes.
ISRCTN54765244
NCT02401685
Query!
Intervention code [1]
318085
0
Not applicable
Query!
Comparator / control treatment
N/A for Extended Follow Up and Data Registry substudy
Query!
Control group
Uncontrolled
Query!
Outcomes
Primary outcome [1]
324447
0
Axillary recurrence defined as the pathologically (cytology or biopsy) and/or radiologically confirmed recurrence in lymph nodes draining the primary tumour site, i.e. nodes in the ipsilateral axilla, infraclavicular fossa, supraclavicular fossa and interpectoral area. Data will be collected via medical records and data linkage to the applicable registry.
Query!
Assessment method [1]
324447
0
Query!
Timepoint [1]
324447
0
Records will be reviewed at 5 years after randomisation to POSNOC to determine the date of axillary recurrence (the date on which imaging or pathology report (whichever comes first) confirms recurrence).
Query!
Secondary outcome [1]
384682
0
Local (breast or chest wall) recurrence is defined as pathologically (cytology or biopsy) and/or radiologically confirmed recurrence after mastectomy in the skin or soft tissue of the chest wall within the anatomical area bounded by the mid-sternal line, the clavicle, the posterior axillary line and the costal margin or any type of breast carcinoma in the breast after conservation therapy. Data will be collected via medical records and data linkage to the applicable registry.
Query!
Assessment method [1]
384682
0
Query!
Timepoint [1]
384682
0
Records will be reviewed at 5 years after randomisation to POSNOC, at 5 years after the last participant is randomised to POSNOC and periodically via data linkage to determine the date of local recurrence (the date on which the imaging or pathology report (whichever comes first) confirms recurrence.)
Query!
Secondary outcome [2]
384683
0
Regional (nodal) recurrence is defined as pathologically (cytology or biopsy) and/or radiologically confirmed recurrent tumour in the lymph nodes in the ipsilateral axilla, infraclavicular, supraclavicular fossa, interpectoral area or ipsilateral internal mammary chain. Data will be collected via medical records and data linkage to the applicable registry.
Query!
Assessment method [2]
384683
0
Query!
Timepoint [2]
384683
0
Records will be reviewed at 5 years after randomisation to POSNOC, at 5 years after the last participant is randomised to POSNOC and periodically via data linkage to determine the date of regional recurrence (the date on which the imaging or pathology report (whichever comes first) confirms recurrence).
Query!
Secondary outcome [3]
384684
0
Distant metastasis is defined as confirmed metastasis (positive pathology and/or definitive evidence on imaging) in all other sites of recurrence and may include those classified as: soft-tissue category, visceral category, central nervous system and skeletal spread. Data will be collected via medical records and data linkage to the applicable registry.
Query!
Assessment method [3]
384684
0
Query!
Timepoint [3]
384684
0
Records will be reviewed at 5 years after randomisation to POSNOC, at 5 years after the last participant is randomised to POSNOC and periodically via data linkage to determine the date of distant metastasis (the date on which imaging or pathology report (whichever comes first) confirms metastasis).
Query!
Secondary outcome [4]
384685
0
Time to axillary recurrence via medical records and data linkage to the AIHW (Australia) and BCFNR (New Zealand).
Query!
Assessment method [4]
384685
0
Query!
Timepoint [4]
384685
0
The time between the date of randomisation and the date of axillary recurrence, measured in days. The date of axillary recurrence is the date on which pathology report confirms recurrence.
Query!
Secondary outcome [5]
384686
0
Axillary recurrence free survival via medical records and data linkage to the AIHW (Australia) and BCFNR (New Zealand)..
Query!
Assessment method [5]
384686
0
Query!
Timepoint [5]
384686
0
The time between the date of randomisation and date of confirmed axillary recurrence or date of death, whichever comes first, measured in days. Participants who did not experience axillary recurrence and are still alive will be censored at the date of last follow up.
Query!
Secondary outcome [6]
384687
0
Disease free survival via medical records and data linkage to the AIHW (Australia) and BCFNR (New Zealand).
Query!
Assessment method [6]
384687
0
Query!
Timepoint [6]
384687
0
The time between the date of randomisation and the date of disease progression (i.e. local or regional recurrence or distant metastasis) or death, whichever comes first, measured in days. Participants who do not have progression and are still alive will be censored at the date of last follow up.
Query!
Secondary outcome [7]
384688
0
Overall survival.
Query!
Assessment method [7]
384688
0
Query!
Timepoint [7]
384688
0
The time between the date of randomisation and the date of death from any cause. Participants who are still alive will be censored at the date of last follow up.
Query!
Secondary outcome [8]
384689
0
Contralateral breast cancer is new primary malignancy in the opposite breast unless obviously contiguous with recurrent chest wall disease or proven on cytology/biopsy to be of metastatic origin via medical records and data linkage to the AIHW (Australia) and BCFNR (New Zealand)..
Query!
Assessment method [8]
384689
0
Query!
Timepoint [8]
384689
0
Records will be reviewed at 5 years after randomisation to POSNOC, at 5 years after the last participant is randomised to POSNOC and periodically via data linkage to determine the date contralateral breast cancer is confirmed.
Query!
Secondary outcome [9]
384690
0
Non-breast cancer is any new non-breast primary malignancy, except for adequately treated, superficial squamous or basal cell carcinoma of the skin, or carcinoma in situ of the cervix via medical records and data linkage to the AIHW (Australia) and BCFNR (New Zealand)..
Query!
Assessment method [9]
384690
0
Query!
Timepoint [9]
384690
0
Records will be reviewed at 5 years after randomisation to POSNOC, at 5 years after the last participant is randomised to POSNOC and periodically via data linkage to determine the date non-breast cancer is confirmed.
Query!
Eligibility
Key inclusion criteria
Extended follow up data will be collected from patients participating in the Main POSNOC study in Australia and New Zealand. Key Inclusion Criteria for POSNOC are as follows:
* 18 years or older
* Unifocal or multi-focal invasive tumour with lesion <=5 cm in its largest dimension, measured pathologically or for women who are randomised intra-operatively largest tumour diameter on mammogram or ultrasound (tumour size should be based only on the single largest tumour; do not add the sizes together from the multiple foci)
* At sentinel node biopsy have 1 or 2 sentinel nodes with macrometastases (tumour deposit >2.0mm in largest dimension or defined as macrometastasis on molecular assay)
* Fit for axillary treatment and adjuvant therapy
* Have given written informed consent
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Extended follow up data will be collected from patients participating in the Main POSNOC study in Australia and New Zealand. Key Exclusion Criteria for POSNOC are as follows:
* bilateral breast cancer
* more than 2 nodes with macrometastases
* neoadjuvant therapy for breast cancer
* previous axillary surgery on the same body side as the scheduled sentinel node biopsy
* not receiving adjuvant systemic therapy
* previous cancer less than 5 years previously or concomitant malignancy except: adequately treated basal or squamous cell carcinoma of the skin; adequately treated in situ carcinoma of the cervix; adequately treated in situ melanoma; contra- or ipsilateral in situ breast cancer.
Query!
Study design
Purpose
Query!
Duration
Query!
Selection
Query!
Timing
Query!
Statistical methods / analysis
POSNOC was designed to assess the need for additional local axillary treatment in those with limited disease in the sentinel node who will be treated with adjuvant systemic therapy. The original plan was for 5 years of follow-up, based on data suggesting that the large majority of regional recurrences occurred within the first 2 years. Recent data suggests that with modern systemic therapy, regional recurrences may be delayed, and therefore extended follow up is important to address the POSNOC hypothesis.
UK participants will be “flagged” after discharge with NHS Digital to collect further health status information. This will avoid causing unnecessary distress to the family, as it will avert inappropriate contact if the woman has died following discharge from hospital-based follow up. It will reduce losses to follow up and will also enable longer term follow up data (greater than 5 years) to be reported.
Data Registry follow up in Australia and New Zealand will be conducted with the same benefits in mind.
It is expected that the addition of complete mortality and cancer incidence data from the Australian and New Zealand participants in addition to that collected in the UK will increase the power of the POSNOC study to determine whether adjuvant therapy alone is no worse than adjuvant therapy plus axillary treatment.
Query!
Recruitment
Recruitment status
Not yet recruiting
Query!
Date of first participant enrolment
Anticipated
13/07/2026
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
Query!
Sample size
Target
208
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,WA,VIC
Query!
Recruitment hospital [1]
22250
0
Bankstown-Lidcombe Hospital - Bankstown
Query!
Recruitment hospital [2]
22251
0
Box Hill Hospital - Box Hill
Query!
Recruitment hospital [3]
22252
0
Breast and Endocrine Centre - Gateshead
Query!
Recruitment hospital [4]
22253
0
Coffs Harbour Base Hospital - Coffs Harbour
Query!
Recruitment hospital [5]
22254
0
Fiona Stanley Hospital - Murdoch
Query!
Recruitment hospital [6]
22255
0
Genesis Cancer Care - Gateshead
Query!
Recruitment hospital [7]
22256
0
Maroondah Hospital - Ringwood East
Query!
Recruitment hospital [8]
22257
0
Mater Adult Hospital - South Brisbane
Query!
Recruitment hospital [9]
22258
0
GenesisCare - Mater Hospital - North Sydney
Query!
Recruitment hospital [10]
22259
0
Monash Medical Centre - Moorabbin campus - East Bentleigh
Query!
Recruitment hospital [11]
22260
0
Riverina Cancer Care Centre - Wagga Wagga
Query!
Recruitment hospital [12]
22261
0
The Royal Adelaide Hospital - Adelaide
Query!
Recruitment hospital [13]
22262
0
Royal Melbourne Hospital - City campus - Parkville
Query!
Recruitment hospital [14]
22263
0
The Royal Women's Hospital - Parkville
Query!
Recruitment hospital [15]
22264
0
Sir Charles Gairdner Hospital - Nedlands
Query!
Recruitment hospital [16]
22265
0
St John of God Hospital, Subiaco - Subiaco
Query!
Recruitment hospital [17]
22266
0
Sunshine Hospital - St Albans
Query!
Recruitment hospital [18]
22267
0
Westmead Hospital - Westmead
Query!
Recruitment postcode(s) [1]
37414
0
2200 - Bankstown
Query!
Recruitment postcode(s) [2]
37415
0
3128 - Box Hill
Query!
Recruitment postcode(s) [3]
37416
0
2290 - Gateshead
Query!
Recruitment postcode(s) [4]
37417
0
2450 - Coffs Harbour
Query!
Recruitment postcode(s) [5]
37418
0
6150 - Murdoch
Query!
Recruitment postcode(s) [6]
37419
0
3135 - Ringwood East
Query!
Recruitment postcode(s) [7]
37420
0
4101 - South Brisbane
Query!
Recruitment postcode(s) [8]
37421
0
2060 - North Sydney
Query!
Recruitment postcode(s) [9]
37422
0
3165 - East Bentleigh
Query!
Recruitment postcode(s) [10]
37423
0
2650 - Wagga Wagga
Query!
Recruitment postcode(s) [11]
37424
0
5000 - Adelaide
Query!
Recruitment postcode(s) [12]
37425
0
3050 - Parkville
Query!
Recruitment postcode(s) [13]
37426
0
6009 - Nedlands
Query!
Recruitment postcode(s) [14]
37427
0
6008 - Subiaco
Query!
Recruitment postcode(s) [15]
37428
0
3021 - St Albans
Query!
Recruitment postcode(s) [16]
37429
0
2145 - Westmead
Query!
Recruitment outside Australia
Country [1]
24737
0
New Zealand
Query!
State/province [1]
24737
0
Query!
Funding & Sponsors
Funding source category [1]
306217
0
Government body
Query!
Name [1]
306217
0
National Health and Medical Research Counco;
Query!
Address [1]
306217
0
GPO Box 1421
Canberra ACT 2601
Query!
Country [1]
306217
0
Australia
Query!
Primary sponsor type
Other Collaborative groups
Query!
Name
Breast Cancer Trials
Query!
Address
PO Box 283
The Junction NSW 2291
Query!
Country
Australia
Query!
Secondary sponsor category [1]
306692
0
Other
Query!
Name [1]
306692
0
Derby Hospitals NHS Foundation Trust
Query!
Address [1]
306692
0
Uttoxeter New Road
Derby DE22 3NE
Query!
Country [1]
306692
0
United Kingdom
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
306429
0
Melbourne Health HREC
Query!
Ethics committee address [1]
306429
0
Office for Research
Level 2 South West
Royal Melbourne Hospital
300 Grattan Street
Parkville VIC 3050
Query!
Ethics committee country [1]
306429
0
Australia
Query!
Date submitted for ethics approval [1]
306429
0
01/06/2022
Query!
Approval date [1]
306429
0
28/06/2022
Query!
Ethics approval number [1]
306429
0
Query!
Summary
Brief summary
POSNOC was designed to assess the need for additional local axillary treatment in those with limited disease in the sentinel node who will be treated with adjuvant systemic therapy. The original plan was for 5 years of follow-up, based on data suggesting that the large majority of regional recurrences occurred within the first 2 years. Recent data suggests that with modern systemic therapy, regional recurrences may be delayed, and therefore extended follow up is important to address the POSNOC hypothesis.
It is expected that the addition of complete mortality and cancer incidence data from the Australian and New Zealand participants in addition to that collected in the UK will increase the power of the POSNOC study to determine whether adjuvant therapy alone is no worse than adjuvant therapy plus axillary treatment.
The objectives of the POSNOC Extended Follow Up and Data Registry substudy are the same as those of the main POSNOC study. The objective of this substudy is to increase the power of the study to address the questions.
Who Is It For?
Patients who are randomized to the ANZ 1501 POSNOC study in Australia and New Zealand (ISRCTN54765244, NCT02401685).
Substudy details:
Data collection in this project will be obtained by:
1. One additional contact in 2026 (when the final patient recruited to POSNOC has reached 5 years of follow up). Data linkage will be used where a patient cannot be contacted; and
2. Subsequent follow up by data linkage. The data will be requested from the respective national and jurisdictional data registries for Australia and New Zealand such as the Australian Institute of Health and Welfare (AIHW) and New Zealand’s Breast Cancer Foundation National Register (BCFNR). Data will be cleaned and securely stored on servers within the Breast Cancer Trials, Trials Department, Newcastle, NSW Australia.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Breast Cancer Trials formerly known as the Australia & New Zealand Breast Cancer Trials Group.
Query!
Contacts
Principal investigator
Name
103838
0
Prof Bruce Mann
Query!
Address
103838
0
Director of The Breast Service
Suite 12
The Royal Women's Hospital
20 Flemington Road
Parkville VIC 3052
Query!
Country
103838
0
Australia
Query!
Phone
103838
0
+61 2 4925 5235
Query!
Fax
103838
0
Query!
Email
103838
0
[email protected]
Query!
Contact person for public queries
Name
103839
0
Ms Corinna Beckmore
Query!
Address
103839
0
Breast Cancer Trials
PO Box 283
The Junction NSW 2291
Query!
Country
103839
0
Australia
Query!
Phone
103839
0
+61 2 4925 5235
Query!
Fax
103839
0
Query!
Email
103839
0
[email protected]
Query!
Contact person for scientific queries
Name
103840
0
Prof Bruce Mann
Query!
Address
103840
0
Director of The Breast Service
Suite 12
The Royal Women's Hospital
20 Flemington Road
Parkville VIC 3052
Query!
Country
103840
0
Australia
Query!
Phone
103840
0
+61 2 4925 5235
Query!
Fax
103840
0
Query!
Email
103840
0
[email protected]
Query!
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
Query!
No/undecided IPD sharing reason/comment
Data Sharing process for this study is in development and will be updated as soon as it is available.
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF